The synergistic effect of PI3K inhibitors has been shown to be much more dramatic in PIK3CA-mutated breast cancer cells than in PIK3CA WT cells, and E545K mutants in exon 9 have shown a relatively poor response to PI3K inhibitor (Liu et al., 2018). The gene discussed is PIK3CA; the disease is breast carcinoma.